Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated:  11/30/2015
City of Hope National Medical Center City of Hope national Med Ctr
mi
from
Duarte, CA
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated: 11/30/2015
City of Hope National Medical Center City of Hope national Med Ctr
mi
from
Duarte, CA
Click here to add this to my saved trials
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated:  11/30/2015
University of California at Los Angeles - UCLA
mi
from
Los Angeles, CA
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated: 11/30/2015
University of California at Los Angeles - UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated:  11/30/2015
California Pacific Medical Center California Pacific Med
mi
from
San Francisco, CA
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated: 11/30/2015
California Pacific Medical Center California Pacific Med
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated:  11/30/2015
University of Colorado Univ Colorado 2
mi
from
Aurora, CO
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated: 11/30/2015
University of Colorado Univ Colorado 2
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated:  11/30/2015
Rush University Medical Center SC
mi
from
Chicago, IL
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated: 11/30/2015
Rush University Medical Center SC
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated:  11/30/2015
Oncology Specialists, SC Dept.of Oncology Specialists
mi
from
Park Ridge, IL
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated: 11/30/2015
Oncology Specialists, SC Dept.of Oncology Specialists
mi
from
Park Ridge, IL
Click here to add this to my saved trials
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated:  11/30/2015
Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Medical Oncology
mi
from
Baltimore, MD
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated: 11/30/2015
Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Medical Oncology
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated:  11/30/2015
Dana Farber Cancer Institute DFCI - Brookline
mi
from
Boston, MA
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated: 11/30/2015
Dana Farber Cancer Institute DFCI - Brookline
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated:  11/30/2015
Mayo Clinic - Rochester Mayo Clinic- Gonda
mi
from
Rochester, MN
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated: 11/30/2015
Mayo Clinic - Rochester Mayo Clinic- Gonda
mi
from
Rochester, MN
Click here to add this to my saved trials
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated:  11/30/2015
Washington University School of Medicine Camn107B2301
mi
from
St. Louis, MO
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated: 11/30/2015
Washington University School of Medicine Camn107B2301
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated:  11/30/2015
Case Western Reserve Case Western
mi
from
Cleveland, OH
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated: 11/30/2015
Case Western Reserve Case Western
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated:  11/30/2015
University of California San Diego - Moores Cancer Center UCSD Moores Cancer Center
mi
from
La Jolla, CA
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated: 11/30/2015
University of California San Diego - Moores Cancer Center UCSD Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated:  11/30/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated: 11/30/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated:  11/30/2015
Baylor Health Care System/Sammons Cancer Center Baylor 2
mi
from
Dallas, TX
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated: 11/30/2015
Baylor Health Care System/Sammons Cancer Center Baylor 2
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated:  11/30/2015
Novartis Investigative Site
mi
from
Buenos Aires,
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Status: Enrolling
Updated: 11/30/2015
Novartis Investigative Site
mi
from
Buenos Aires,
Click here to add this to my saved trials
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors
Status: Enrolling
Updated:  11/30/2015
Billings Clinic
mi
from
Billings, MT
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors
Status: Enrolling
Updated: 11/30/2015
Billings Clinic
mi
from
Billings, MT
Click here to add this to my saved trials
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors
Status: Enrolling
Updated:  11/30/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors
Status: Enrolling
Updated: 11/30/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors
Status: Enrolling
Updated:  11/30/2015
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors
Status: Enrolling
Updated: 11/30/2015
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Click here to add this to my saved trials
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors
Status: Enrolling
Updated:  11/30/2015
Ottawa Health Research Institute
mi
from
Ottawa,
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors
Status: Enrolling
Updated: 11/30/2015
Ottawa Health Research Institute
mi
from
Ottawa,
Click here to add this to my saved trials
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated:  12/2/2015
Cancer and Blood Institute of the Desert
mi
from
Rancho Mirage, CA
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated: 12/2/2015
Cancer and Blood Institute of the Desert
mi
from
Rancho Mirage, CA
Click here to add this to my saved trials
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated:  12/2/2015
Yale Comprehensive Cancer Center
mi
from
New Haven, CT
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated: 12/2/2015
Yale Comprehensive Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated:  12/2/2015
Columbia - HCA Cancer Research Network
mi
from
North Miami Beach, FL
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated: 12/2/2015
Columbia - HCA Cancer Research Network
mi
from
North Miami Beach, FL
Click here to add this to my saved trials
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated:  12/2/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated: 12/2/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated:  12/2/2015
Georgia Cancer Specialists
mi
from
Decatur, GA
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated: 12/2/2015
Georgia Cancer Specialists
mi
from
Decatur, GA
Click here to add this to my saved trials
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated:  12/2/2015
University of Illinois at Chicago
mi
from
Chicago, IL
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated: 12/2/2015
University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated:  12/2/2015
Lutheran General Cancer Care Center
mi
from
Park Ridge, IL
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated: 12/2/2015
Lutheran General Cancer Care Center
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated:  12/2/2015
James Graham Brown Cancer Center
mi
from
Louisville, KY
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated: 12/2/2015
James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated:  12/2/2015
Cancer and Hematology Centers of Western Michigan
mi
from
Grand Rapids, MI
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated: 12/2/2015
Cancer and Hematology Centers of Western Michigan
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated:  12/2/2015
Hubert H. Humphrey Cancer Center
mi
from
Robbinsdale, MN
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated: 12/2/2015
Hubert H. Humphrey Cancer Center
mi
from
Robbinsdale, MN
Click here to add this to my saved trials
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated:  12/2/2015
Midwest Oncology Consortium
mi
from
Kansas City, MO
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated: 12/2/2015
Midwest Oncology Consortium
mi
from
Kansas City, MO
Click here to add this to my saved trials
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated:  12/2/2015
Jersey Shore Cancer Center
mi
from
Neptune, NJ
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated: 12/2/2015
Jersey Shore Cancer Center
mi
from
Neptune, NJ
Click here to add this to my saved trials
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated:  12/2/2015
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated: 12/2/2015
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated:  12/2/2015
Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated: 12/2/2015
Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated:  12/2/2015
University of Pennsylvania Cancer Center
mi
from
Philadelphia, PA
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated: 12/2/2015
University of Pennsylvania Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated:  12/2/2015
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
mi
from
Philadelphia, PA
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated: 12/2/2015
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated:  12/2/2015
Palmetto Hematology Oncology Associates
mi
from
Spartanburg, SC
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Status: Enrolling
Updated: 12/2/2015
Palmetto Hematology Oncology Associates
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
M-Vax: A Feasibility and Bio-Equivalence Study Using a DNP-Modified Autologous Melanoma Tumor Cell Vaccine as Therapy in Patients With Stage III or IV Melanoma
Status: Enrolling
Updated:  12/2/2015
University of Arizona Cancer Center
mi
from
Tucson, AZ
Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
M-Vax: A Feasibility and Bio-Equivalence Study Using a DNP-Modified Autologous Melanoma Tumor Cell Vaccine as Therapy in Patients With Stage III or IV Melanoma
Status: Enrolling
Updated: 12/2/2015
University of Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
M-Vax: A Feasibility and Bio-Equivalence Study Using a DNP-Modified Autologous Melanoma Tumor Cell Vaccine as Therapy in Patients With Stage III or IV Melanoma
Status: Enrolling
Updated:  12/2/2015
Pacific Oncology and Hematology Associates
mi
from
San Diego, CA
Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
M-Vax: A Feasibility and Bio-Equivalence Study Using a DNP-Modified Autologous Melanoma Tumor Cell Vaccine as Therapy in Patients With Stage III or IV Melanoma
Status: Enrolling
Updated: 12/2/2015
Pacific Oncology and Hematology Associates
mi
from
San Diego, CA
Click here to add this to my saved trials
Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
M-Vax: A Feasibility and Bio-Equivalence Study Using a DNP-Modified Autologous Melanoma Tumor Cell Vaccine as Therapy in Patients With Stage III or IV Melanoma
Status: Enrolling
Updated:  12/2/2015
University of Illinois School of Medicine
mi
from
Chicago, IL
Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
M-Vax: A Feasibility and Bio-Equivalence Study Using a DNP-Modified Autologous Melanoma Tumor Cell Vaccine as Therapy in Patients With Stage III or IV Melanoma
Status: Enrolling
Updated: 12/2/2015
University of Illinois School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
M-Vax: A Feasibility and Bio-Equivalence Study Using a DNP-Modified Autologous Melanoma Tumor Cell Vaccine as Therapy in Patients With Stage III or IV Melanoma
Status: Enrolling
Updated:  12/2/2015
University of Louisville
mi
from
Louisville, KY
Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
M-Vax: A Feasibility and Bio-Equivalence Study Using a DNP-Modified Autologous Melanoma Tumor Cell Vaccine as Therapy in Patients With Stage III or IV Melanoma
Status: Enrolling
Updated: 12/2/2015
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
M-Vax: A Feasibility and Bio-Equivalence Study Using a DNP-Modified Autologous Melanoma Tumor Cell Vaccine as Therapy in Patients With Stage III or IV Melanoma
Status: Enrolling
Updated:  12/2/2015
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
M-Vax: A Feasibility and Bio-Equivalence Study Using a DNP-Modified Autologous Melanoma Tumor Cell Vaccine as Therapy in Patients With Stage III or IV Melanoma
Status: Enrolling
Updated: 12/2/2015
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
M-Vax: A Feasibility and Bio-Equivalence Study Using a DNP-Modified Autologous Melanoma Tumor Cell Vaccine as Therapy in Patients With Stage III or IV Melanoma
Status: Enrolling
Updated:  12/2/2015
Thomas Jefferson University
mi
from
Philadelphia, PA
Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
M-Vax: A Feasibility and Bio-Equivalence Study Using a DNP-Modified Autologous Melanoma Tumor Cell Vaccine as Therapy in Patients With Stage III or IV Melanoma
Status: Enrolling
Updated: 12/2/2015
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
M-Vax: A Feasibility and Bio-Equivalence Study Using a DNP-Modified Autologous Melanoma Tumor Cell Vaccine as Therapy in Patients With Stage III or IV Melanoma
Status: Enrolling
Updated:  12/2/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
M-Vax: A Feasibility and Bio-Equivalence Study Using a DNP-Modified Autologous Melanoma Tumor Cell Vaccine as Therapy in Patients With Stage III or IV Melanoma
Status: Enrolling
Updated: 12/2/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant
A Phase IIb Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Topical Bacteriophage T4 Endonuclease V in Renal Allograft Recipients With a History of Non-melanoma Skin Cancer
Status: Enrolling
Updated:  12/3/2015
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant
A Phase IIb Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Topical Bacteriophage T4 Endonuclease V in Renal Allograft Recipients With a History of Non-melanoma Skin Cancer
Status: Enrolling
Updated: 12/3/2015
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma
A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma
Status: Enrolling
Updated:  12/9/2015
Clinical Research Facility
mi
from
Dallas, TX
A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma
A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma
Status: Enrolling
Updated: 12/9/2015
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma
A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma
Status: Enrolling
Updated:  12/9/2015
Clinical Research Facility
mi
from
Houston, TX
A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma
A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma
Status: Enrolling
Updated: 12/9/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
Phase IA/IB Trial of Modulation of the Biological Response to Interleukin-2 (IL-2) With Bryostatin 1 (BRYO; NSC 339555)
Status: Enrolling
Updated:  12/10/2015
Norris Cotton Cancer Center
mi
from
Lebanon, NH
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
Phase IA/IB Trial of Modulation of the Biological Response to Interleukin-2 (IL-2) With Bryostatin 1 (BRYO; NSC 339555)
Status: Enrolling
Updated: 12/10/2015
Norris Cotton Cancer Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
Phase IA/IB Trial of Modulation of the Biological Response to Interleukin-2 (IL-2) With Bryostatin 1 (BRYO; NSC 339555)
Status: Enrolling
Updated:  12/10/2015
Massey Cancer Center
mi
from
Richmond, VA
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
Phase IA/IB Trial of Modulation of the Biological Response to Interleukin-2 (IL-2) With Bryostatin 1 (BRYO; NSC 339555)
Status: Enrolling
Updated: 12/10/2015
Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Phase II Study to Evaluate the Safety, Tolerability and Efficacy of CT-011 Administered Intravenously to Patients With Metastatic Melanoma
Status: Enrolling
Updated:  12/16/2015
Yale University School of Medicine, Section of Med Onc.
mi
from
New Haven, CT
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Phase II Study to Evaluate the Safety, Tolerability and Efficacy of CT-011 Administered Intravenously to Patients With Metastatic Melanoma
Status: Enrolling
Updated: 12/16/2015
Yale University School of Medicine, Section of Med Onc.
mi
from
New Haven, CT
Click here to add this to my saved trials
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Phase II Study to Evaluate the Safety, Tolerability and Efficacy of CT-011 Administered Intravenously to Patients With Metastatic Melanoma
Status: Enrolling
Updated:  12/16/2015
Moffitt Cancer Center Cutaneous Oncology Department
mi
from
Tampa, FL
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Phase II Study to Evaluate the Safety, Tolerability and Efficacy of CT-011 Administered Intravenously to Patients With Metastatic Melanoma
Status: Enrolling
Updated: 12/16/2015
Moffitt Cancer Center Cutaneous Oncology Department
mi
from
Tampa, FL
Click here to add this to my saved trials